AlphaNavi Pharma

AlphaNavi Pharma is a clinical-stage biopharmaceutical company based in Japan that specializes in the development of novel treatments for chronic pain. Spun out from Mitsubishi Tanabe Pharma Corporation, the company focuses on targeting voltage-gated sodium channels, particularly Nav1.7, to address high unmet needs in neuropathic pain. Its lead candidate, ANP-230, is a highly selective Nav1.7 inhibitor currently being evaluated in Phase 2 clinical trials for indications such as post-herpetic neuralgia. By leveraging its expertise in ion channel drug discovery, AlphaNavi aims to provide safer and more effective alternatives to current analgesics. The company is supported by a strong network of investors and strategic partners within the Japanese pharmaceutical ecosystem.